# A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disease in the United Kingdom (UK)

> **NCT07242248** · — · RECRUITING · sponsor: **Janssen-Cilag Ltd.** · enrollment: 220 (estimated)

## Conditions studied

- Inflammatory Bowel Disease
- Colitis, Ulcerative
- Crohn's Disease

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07242248
- **Lead sponsor:** Janssen-Cilag Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-17
- **Primary completion:** 2029-03-05
- **Final completion:** 2029-03-17
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07242248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07242248, "A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disease in the United Kingdom (UK)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT07242248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*